
Biotinylated Human HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein Cont No. MHC-HE007B

Cat. No. MHC-HE007B

Description	
Source	Recombinant Biotinylated Human HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-terminus.
	It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KLVVVGAVGV peptide.
Accession	A0A140T913(HLA-A*02:01)&P61769(B2M)&KLVVVGAVGV
Molecular Weight	The protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC
Formulation and	Storage
Formulation	Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background	
	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high priority therapoutic target. The virtual screeping approach to discover nevel KRAS inhibitors

makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

10KD SEC-HPLC




Biotinylated Human HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Biotinylated Human HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein Control Cont

MHC-HE007B Cat. No.

Assay Data



The purity of Biotinylated Human HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer is greater than 95% as determined by SEC-HPLC.